Key facts
- This page summarizes Eric Warren's Form 4 filing for Esperion Therapeutics, Inc. (ESPR).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 20 Feb 2025, 16:50.
Eric Warren - 19 Feb 2025 Form 4 Insider Report for Esperion Therapeutics, Inc. (ESPR)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- ESPR
- Reported as of
- 19 Feb 2025
- Net transaction value
- -$446
- SEC form
- 4
- Accepted by SEC
- 20 Feb 2025, 16:50:44 UTC
- Prior SEC filing
- 21 Jan 2025
- Next SEC filing
- 17 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sheldon L. Koenig, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Warren filed Form 4 for Esperion Therapeutics, Inc. (ESPR) on 20 Feb 2025.
Change
- Previous filing in this sequence was filed on 21 Jan 2025.
- Current net transaction value: -$446.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ESPR
transaction
Common Stock
Sale
- Transaction value
- $446
- Shares
- -239
- Change %
- -0.15%
- Price
- $1.87
- Shares after
- 159,759
- Date
- 19 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Shares were sold to satisfy tax obligation on vested shares of restricted stock units.